Cognitive-Sensorimotor Function in Long-COVID

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVA Office of Research and Development

About this trial

Growing evidence indicates that many people who have chronic post-acute sequelae of SARS-CoV-2 infection (PASC) will experience ongoing neurological and musculoskeletal impairment that can affect gait and balance. Identifying the factors contributing to these impairments and how they influence functional mobility is the first step towards creating effective evaluation and treatment protocols. In this study the investigators will examine cognition, vision, proprioception, muscle strength, gait and balance in persons with and without PASC to understand how PASC may impact functional mobility through a cognitive-sensorimotor lens. Gait and balance will be studied in environments that stress cognitive and sensory abilities. Study outcomes will be critical for the development of evidence-based Veteran Health Administration diagnostic and standard-of-care protocols to address gait and balance dysfunction in Veterans with PASC for restoring their functional mobility and independence.

Eligibility criteria

Qualifiers

Older than 18 years of age

Positive PCR or Rapid COVID-19 test in the past

Onset of COVID-19 illness greater than 3 months prior to their participation in the study

Self-reported ability to walk 10 meters with or without external assistance prior to COVID-19 illness

Disqualifiers

Presence of severe cardiovascular and pulmonary disease and/or neurological and musculoskeletal disorders unrelated to COVID-19 (e.g., amputation, stroke, spinal cord injury)

Cognitive impairments precluding ability to provide informed consent.

Severe acute COVID-19 infection requiring hospitalization or diagnosed post-intensive care syndrome.

Presence of musculoskeletal, inflammatory, or neurological conditions mimicking Long COVID-19 symptoms (e.g., concussion within last 5 years, Chronic fibromyalgia, Myofascial pain syndrome, etc.)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

136 Participants
are grouped into 2 trial groups

Sponsors and collaborators

VA Office of Research and Development

Lead sponsor

Edward Hines Jr. VA Hospital

Collaborator